Skip to ContentSkip to Navigation
About us Latest news News News articles

Off-target effects of RAAS-inhibition: importance on renal outcomes in patients with diabetes

21 May 2012

PhD ceremony: Ms. Y. Miao, 11.00 uur, Academiegebouw, Broerstraat 5, Groningen

Dissertation: Off-target effects of RAAS-inhibition: importance on renal outcomes in patients with diabetes

Promotor(s): prof. D de Zeeuw, prof. D.E. Grobbee

Faculty: Medical Sciences

Drug development for patients with diabetes and nephropathy is based on effectiveness assessment of a single risk factor for renal and cardiovascular diseases (the so-called on-target risk factor). This effect is used to estimate the effect of the drug on clinically relevant endpoints. In addition, several parameters are evaluated to assess the safety of the drug. However, drugs exert effects on more risk factors than just the on-target risk factor. These so-called off-target effects ultimately affect the drug effectiveness on clinical endpoints, either positively or negatively.

In this thesis, the off-target effects of angiotensin II antagonists in patients with type 2 diabetes and nephropathy were studied. The ultimate aim is to develop a risk score that combines all the short-term on-target and off-target effects of a drug, and that produces a better estimate of the effectiveness of a drug on hard clinical endpoints. The results show that the effect of the AIIA losartan on uric acid after 6 months of therapy contributes to its ultimate renal protective effect. On the other hand, we demonstrated that the effect of losartan on serum potassium negatively influences the renal protective effect of losartan. When all the short-term off-target and on-target effects are combined in an algorithm, an accurate estimate of the final drug effect is obtained, in a much better way than when only the on-target effect is taken into consideration. This finding has important implications for drug development, registration, and individual patient care.

Last modified:13 March 2020 01.00 a.m.
View this page in: Nederlands

More news

  • 29 November 2023

    UMCG opent nieuwe faciliteit voor microbioomonderzoek 

    Vandaag opent het UMCG de Groningen Microbioom Hub: een nieuwe faciliteit met state-of-the-art technologie waarin alle UMCG-expertise op het gebied van microbioomonderzoek samenkomt. Dit zorgt voor unieke mogelijkheden in onderzoek en maakt nieuwe...

  • 28 November 2023

    Science: more exciting than showbiz

    Science often seems very complicated. Most people probably don't really know what researchers do, and what it takes to make a breakthrough. That is why it is important to keep the general public informed of what is happening in science, says Iris...

  • 13 November 2023

    UMCG beantwoordt vragen patiënten met hulp van AI

    Het UMCG zet kunstmatige intelligentie (artificial intelligence, afgekort AI) in om zorgverleners te helpen bij het beantwoorden van schriftelijke vragen van patiënten. Dit gebeurt in samenwerking met andere ziekenhuizen vanuit de EPIC Nederlandse...